Literature DB >> 24416848

COPD exacerbations -- a comparison of Irish data with European data from the ERS COPD Audit.

S Crinion1, O Cotter1, B Kennedy1, B O'Connor1, D R Curran1, S McCormack2, T J McDonnell3, T M O'Connor1.   

Abstract

The European Respiratory Society COPD audit was a cross-sectional, multicentre study that analysed outcomes for COPD patients admitted to hospital with an exacerbation across Europe. We present the data on patients admitted to 11 Irish hospitals that participated in the audit. Among 237 patients (123 Male), the median age was 71 years and 79 (33%) patients were current smokers. 82 (35%) patients received high-flow oxygen before admission and 43 (18%) were cared for in a dedicated respiratory ward. 54 (23%) patients required ventilatory support. Median length of stay was 7 days, 98 (41%) patients were readmitted and 211 (89%) patients were alive at the 90 day follow up point. Irish patients were more likely to receive high-flow oxygen before admission, less likely to be managed in a dedicated respiratory ward and had a higher likelihood of readmission or death within 90 days than the European average.

Entities:  

Mesh:

Year:  2013        PMID: 24416848

Source DB:  PubMed          Journal:  Ir Med J        ISSN: 0332-3102


  3 in total

Review 1.  Acute exacerbation of COPD: is it the "stroke of the lungs"?

Authors:  Georgios Hillas; Fotis Perlikos; Nikolaos Tzanakis
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-07-13

2.  Identifying priorities for primary care investment in Ireland through a population-based analysis of avoidable hospital admissions for ambulatory care sensitive conditions (ACSC).

Authors:  Geraldine McDarby; Breda Smyth
Journal:  BMJ Open       Date:  2019-11-05       Impact factor: 2.692

3.  D-dimer/Fibrinogen ratio and recurrent exacerbations might have a potential impact to predict 90-day mortality in patients with COPD exacerbation.

Authors:  Cihan Aydin; Birsen Pınar Yıldız; Didem Görgün Hattatoğlu
Journal:  Malawi Med J       Date:  2021-12       Impact factor: 0.875

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.